DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
[Docket No. 75F-0355]
ASPARTAME
DECISION OF THE PUBLIC BOARD OF INQUIRY
I. BACKGROUND ............................................................... 1

II. PRELIMINARY MATTERS ............................................... 6

III. ISSUE NUMBER 1 ...................................................... 9

IV. ISSUE NUMBER 2 ....................................................... 39

V. ISSUE NUMBER 3 ....................................................... 49

VI. ORDER ................................................................. 50
I. BACKGROUND

The Commissioner of Food and Drugs has appointed a Public Board of Inquiry to conduct a hearing involving the long-standing controversy concerning the safety of aspartame for human consumption. Aspartame essentially is a dipeptide composed of the amino acids phenylalanine and aspartic acid. It has an intensely sweet taste, 180-200 times stronger than that of sucrose.

In the Federal Register of March 5, 1973 (38 Fed. Reg. 5921), the Food and Drug Administration (FDA) announced that a petition (FAP 3A2885) had been filed by G. D. Searle & Co., Box 5110, Chicago, Illinois 60680, proposing the issuance of a food additive regulation to provide for the safe use of aspartame (L-aspartyl-L-phenylalanine methyl ester) in foods as a nutritive substance with intense sweetness and with flavor-enhancing properties. The petition was filed under section 409 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 348.

In the Federal Register of July 26, 1974 (39 Fed. Reg. 27317), FDA, after evaluating data in the petition and other relevant material, issued a regulation, now codified at 21 CFR 172.804, prescribing the conditions under which aspartame could be safely used. The regulation approved the use of
aspartame in food as a sweetening agent or for an authorized
technological purpose in foods for which standards of
identity established under section 401 of the Act (21 U.S.C.
341) do not preclude such use. Aspartame was specifically
approved for use as a sweetener in the following foods:

(a) Dry, free-flowing sugar substitutes for table use
(not to include use in cooking) in package units not to
exceed the sweetening equivalent of 2 teaspoonfuls of sugar.

(b) Sugar substitute tablets for sweetening hot
beverages, including coffee and tea. L-leucine was approved
for use as a lubricant in the manufacture of such tablets at
a level not to exceed 3.5 percent of the weight of the
tablet.

(c) Cold breakfast cereals.

(d) Chewing gum.

(e) Dry bases for:

(i) Beverages;

(ii) Instant coffee and tea;
(iii) Gelatins, puddings, and fillings; and

(iv) Dairy product analog toppings.

Aspartame was also approved for use as a flavor enhancer in chewing gum.

The regulation required the label of any food containing aspartame to bear, either on the principal display or on the information panel, the following statement: "PHENYLKETONURICS: CONTAINS PHENYLALANINE." The regulation also required that when aspartame was to be used in a sugar substitute for table use, its label was to bear instructions not to use aspartame in cooking or baking. Finally, if the food containing aspartame purported or was represented for special dietary uses, it was required to be labeled in compliance with special dietary foods regulations.

John W. Olney, M.D., and, jointly, James S. Turner and LABEL, Inc. objected to the regulation and requested a formal evidentiary hearing on certain issues they identified concerning the safety of aspartame. According to these objections, aspartame should not have been approved as a substitute for sucrose, for the reason that it would expose the human being—and especially the unborn child and the infant—to a considerable risk of brain damage leading to
either mental retardation or endocrine dysfunction, or both. Added to this objection were questions concerning a possible potential of aspartame to contribute to the incidence of brain tumors.

The two objecting parties subsequently waived their right to a formal evidentiary hearing and requested, instead, that the agency establish a Public Board of Inquiry to consider the issues raised by their objections to the food additive regulation. After a preliminary audit of Searle's studies raised certain questions about how the studies were conducted, FDA, in the Federal Register of December 5, 1975 (40 Fed. Reg. 56907), imposed a stay of the regulation authorizing the use of aspartame and announced that the establishment of a Public Board of Inquiry would be postponed until the questions raised by the audit were resolved.

The data in question were subsequently reviewed by FDA and by the Universities Associated for Research and Education in Pathology (UAREP). Both UAREP and FDA concluded that the data submitted by Searle were authentic.

In the Federal Register of June 1, 1979 (44 Fed. Reg. 31716), the Commissioner announced that a hearing before a Public Board of Inquiry would be held on the issues raised by the objections to the aspartame food additive regulation.
The questions addressed to the Board by the Commissioner are phrased in the form of three Issues. One of these (Issue Number 1) refers to the question whether aspartame consumption indeed, as claimed by the objecting parties, might entail a risk of brain damage resulting in mental retardation, endocrine dysfunction, or both. A second Issue (Issue Number 2) phrases the question whether aspartame consumption indeed, as claimed by the objecting parties, might increase the incidence of brain tumors. The Board was then asked to decide, based upon its answers to these two questions, whether aspartame should be allowed for use in foods or whether the approval of aspartame should be withdrawn (Issue Number 3).

In accordance with 21 CFR 13.10, nominees for members of the Public Board of Inquiry were submitted to the Commissioner, and on August 16, 1979, the undersigned were selected as members of the Board.

A prehearing conference was held by telephone on January 14, 1980, between the Board and the following persons who requested to participate in the hearing: the Bureau of Foods of the FDA; G. D. Searle & Co.; Dr. Olney; Mr. Turner; Lloyd J. Filer, Jr., M.D.; and Richard J. Wurtman, M.D. Thereafter, pursuant to a Federal Register notice of January 15, 1980 (45 Fed. Reg. 2908) announcing
the time and place of the hearing, evidence concerning the
three Issues was submitted to the Board and heard at a public
session in Rockville, Maryland, on January 30 through
February 1, 1980. The Board also consulted at the hearing
with William Nyhan, M.D., and Milton Brightman, M.D.
Post-hearing briefs were filed by the Bureau of Foods,
G. D. Searle & Co., Dr. Olney, and Mr. Turner. This Initial
Decision represents the Board's deliberations over the
evidence that was presented.

II. PRELIMINARY MATTERS

A. Mr. Turner's Request for Another Hearing

On February 27, 1980, Mr. Turner asked the Board to
reconsider its decision at the public hearing not to consider
certain information concerning the quality of the data
contained in the record. Mr. Turner objected to the Board's
decision, arguing that it was tantamount to a decision not to
examine the "scientific validity" of the studies FDA relied
on to establish the safety of aspartame. Mr. Turner argued
that the Board is required to make such an examination as
part of its responsibility to determine the safety of
aspartame. In his appeal, Mr. Turner requested the Board to
reconvene a public session to consider evidence on such
issues.
The Board does not agree with Mr. Turner's statement that it has refused to hear evidence relating to scientific validity. Mr. Turner uses the term "scientific validity" to describe questions about the authenticity, reliability, and accuracy of the data submitted by Searle and relied on by the FDA in determining the safety of aspartame. Those questions were considered and resolved by the FDA and UAREP before convening this Board. Because it would be impossible for the Board to undertake a retrospective quality inspection of all the studies presented to it, the Board was not charged with making such an examination. The Board did not exclude evidence relating to the quality or appropriateness of the experimental design of the studies or the scientific conclusions that can validly be drawn from the studies. The Board believes that questions involving the proper interpretation of the data are, in fact, questions relating to scientific validity. Thus, although the Board has decided that it should not repeat UAREP's authentication of the data, it has not decided to ignore questions concerning the scientific validity of the studies.

The Board believes that its authority and responsibilities in this public proceeding are clearly delineated in the statement of issues published in the Federal Register of June 1, 1979 (44 Fed. Reg. 31716). Questions involving the authenticity, reliability, and accuracy of the data have
already been resolved by FDA and UAREP and, therefore, are not encompassed within the scope of this hearing. Also, the regulation prescribing the procedures to be followed by the Board provides that the Chairman may schedule a second hearing only if he concludes that such a hearing is necessary in order to "fully and fairly present information that cannot otherwise adequately be considered and to properly resolve the issues." 21 C.F.R. 13.30(e). The Board has concluded that, since it has not been asked by the Commissioner to consider the types of questions raised by Mr. Turner, it is not necessary to hold another hearing to consider such evidence.

B. The Glutamate Association's Request to be Designated as a Participant

The first issue in this hearing is whether the ingestion of aspartame, either alone or together with glutamate, poses a risk of contributing to mental retardation, brain damage, or undesirable effects on neuroendocrine regulatory systems. On July 12, 1979, the Glutamate Association wrote to FDA reserving the right to participate in this proceeding if glutamate per se or its safety were called into question. The Association restated its position in a letter to the Board dated January 22, 1980.
On February 27, 1980, the Glutamate Association requested permission from the Board to participate in the proceeding for the purpose of providing for the record certain scientific comments prepared by the International Glutamate Technical Committee. The Association stated that it wished to participate because it believed that at the hearing Dr. Oiney had raised questions relating to the safety of glutamate alone.

The Board has decided to grant permission to the Glutamate Association to participate in this hearing for the limited purpose of providing for the record scientific comments prepared by the International Glutamate Technical Committee. These comments are based on materials already in the record and, therefore, should not prejudice the other participants.

III. ISSUE NUMBER 1

The question has been raised whether the ingestion of aspartame, either alone or together with glutamate, poses a risk of contributing to mental retardation, brain damage, or undesirable effects on neuroendocrine regulatory systems. From available evidence, what can be concluded in relation to this question? The objecting parties believe that the ingestion of aspartame, either alone or together with glutamate, does pose a risk of contributing to these effects. The Bureau of Foods believes that the
ingestion of aspartame, either alone or together with glutamate, does not pose a risk of contributing to these effects. 44 Fed. Reg. 31717.

The Board decided that this question needs to be addressed under two separate headings, one referring to the neurotoxic potential of aspartame's phenylalanine moiety, the second to the neurotoxic potential of its other amino-acid moiety, aspartic acid. The reason for this is that aspartame's two component amino acids are each associated with a particular form of brain damage: phenylalanine with the diffuse neuropathology underlying phenylketonuric mental retardation, and aspartic acid with a different and more focal form of nerve cell damage affecting foremost the infundibular region of the hypothalamus and thereby inducing endocrine disorders. Since both of aspartame's component amino acids, phenylalanine and aspartic acid, are normal constituents of nearly all of the protein structures that compose our bodily tissues, are normally present in blood plasma, and are ingested in considerable amounts as components of natural foods, animal as well as vegetable, it is a priori clear that they can exert their respective neurotoxic effects only when reaching abnormally high concentrations in the blood plasma. Such hazardous concentration could be thought to result either from excessive oral ingestion or parenteral administration.
(systemic injection) of these amino acids, or—as in the case of phenylketonuria—from the absence of an enzyme crucially involved in their metabolism.

The questions to be addressed with respect to both amino acids composing the aspartame molecule follow naturally from these considerations. They are:

1. At what concentration in the blood plasma do the amino acids at issue begin to pose a risk of brain damage?

2. In what amount would aspartame have to be consumed to induce such hazardous plasma—amino acid concentrations, either when ingested alone or when taken together with foods or with other food additives?

A. Diffuse Brain Damage Associated With Abnormally High Plasma-Phenylalanine Levels: Phenylketonuria

Phenylketonuria (PKU) is an inherited disorder in the metabolism of phenylalanine. It is transmitted by an autosomal recessive gene, and its incidence in the United States is about 1 in 15,000. The disorder results from the absence of an enzyme (phenylalanine hydroxylase) that converts phenylalanine (PHE) to tyrosine; as a consequence
PHE accumulates in body tissues—including blood—in abnormally high concentration: in untreated phenylketonurics plasma-PHE levels usually range between 120-600 μmol/dl (20-100 mg %) instead of the normal 6-12 umol/dl. Through mechanisms not yet fully understood, these grossly elevated PHE concentrations are correlated with severely impaired development of the immature brain in general, and of the myelin sheaths of its nerve fibers in particular. The clinical consequence of this developmental impairment is a profound mental retardation, often accompanied by epileptic seizures and chronic dermatitis. Children born with the enzyme deficiency can develop to adults of normal intelligence, provided their condition is recognized soon after birth, and appropriate dietary treatment instituted promptly thereafter. It is estimated that the PKU newborn loses one percentage point of future intellectual capacity for each postnatal week the condition goes unrecognized (cf. Dr. Richard Koch's testimony at the public hearing).

Treatment is aimed at keeping plasma-PHE concentrations at or below 70-80 umol/dl by restricting the dietary intake of PHE. If this preventative regimen is to be successfully maintained, families with a phenylketonuric child must impose upon the child a strict dietary discipline that cannot be relaxed until the child is adolescent. It is important to note, however, that phenylketonuric mental retardation is conditional upon sustained high plasma levels of PHE, in
contrast to the more focal brain damage that can result—as will be emphasized in a subsequent section—from a single, short-lived surge of glutamic or aspartic acid concentration in the blood plasma.

The essential question with which the Board found itself confronted in examining the phenylalanine issue is: at what level of ingestion could aspartame induce a rise in plasma-PHE concentration to 100 µmol/dl or higher—the levels associated with impaired brain development? It is clear that this question is of particular importance in the case of children under 12, whose brain is still immature, and in the case of women in the child-bearing age. The importance of the question for the latter category is accentuated by the well-established fact that the placenta maintains between the maternal and fetal circulations a 1:2 gradient in the plasma concentrations of most amino acids, including phenylalanine. This means that for the fetal plasma-PHE concentration to reach the 100 umol/dl level, the maternal plasma-PHE concentration needs to rise no higher than 50 umol/dl.

Of the evidence presented the Board considers the following data of particular significance:

1. In normal human adults, the ingestion of a single loading dose of 34 mg/kg body weight aspartame (the 99th
percentile of projected aspartame consumption for an entire
day) dissolved in orange juice induces a rise in plasma-PHE
concentration from a fasting level of 6 μmol/dl to 11
μmol/dl, a level normally found in adults and children
following ingestion of a protein-rich meal. This peak value
is reached about one hour after the aspartame ingestion, and
recedes to fasting level within about 8 hours.

Ingestion of larger loading doses induces proportion-
ately higher plasma-PHE elevations. A 50 mg/kg loading dose
(in a 60 kg person 3000 mg aspartame, or 150 aspartame
tablets, or 6 liters of aspartame-sweetened beverage, but
with its 50% content of PHE equivalent to less than half the
4000 mg PHE contained in one 4-oz. hamburger) causes the
plasma-PHE level to rise from 6 to 16 μmol/dl. Following a
100 mg/kg loading dose (equivalent to 12 liters of
aspartame-sweetened beverage consumed in a single setting)
the plasma-PHE level rises to 20 μmol/dl. Only a 200 mg/kg
loading dose was found to induce a rise to 50 μmol/dl, and
only following this very large dose did the plasma-PHE
concentration take more than 8 hours to return to baseline.
This 200 mg/kg dose corresponds to 600 aspartame tablets, or
24 liters of aspartame-sweetened beverage consumed in a
single sitting by a 60-kg adult, or to 100 tablets of 20 mg
aspartame accidentally ingested by a 3-year old child. Only
in this grossly abusive amount could aspartame ingested by a
pregnant woman be expected to induce plasma-PHE concentrations high enough to cause, through placental transfer, fetal plasma-PHE levels approaching--for a few hours at least--the lower limit of potential toxicity. However, it seems inconceivable that so large a dose would be taken in a single sitting. When consumed over a 16-hour period--as would seem nearly unavoidable--it would undoubtedly induce a more sustained plasma-PHE elevation remaining well below the 50 umol/dl peak induced by the same amount of aspartame taken as a loading dose.

2. In the normal one-year old infant, a loading dose of 34 mg/kg body weight causes the plasma-PHE concentration to rise from a fasting level of 6 umol/dl to 10 µmol/dl, receding to baseline within 4 hours. It appears from this finding that the 1-year old normal child metabolizes PHE at least as effectively as does the normal adult.

3. In individuals heterozygous for phenylketonuria, a 34 mg/kg loading dose of aspartame induces a higher and longer-lasting plasma-PHE elevation. Instead of the 11 µmol/dl peak resulting from such a loading dose in the normal human, the peak reaches 16 µmol/dl in the PKU heterozygote and, in addition, the plasma-PHE curve declines more slowly than it does in normal individuals. A loading dose of 100 mg/kg aspartame--an abuse load even when ingested over a
16-hour period—is followed by a plasma-PHE rise reaching 42 umol/dl, about twice as high as in the normal human. Even following this enormous single load, however, the peak value remains below the level at which, in the case of a pregnant woman, a risk to her unborn child might arise. Moreover, an abuse dose of 100 mg/kg aspartame would in the real-life situation not be ingested in a single sitting, as it was in the cited experiments, but, rather, consumed over an extended time period. Under these more natural conditions, the plasma-PHE concentration could be expected to remain well below the 42 umol/dl level. It is of interest to note that a 100 mg/kg intake of aspartame by a 60-kg woman would add less to her dietary PHE consumption than would be added by an extra 4-oz. hamburger: 3000 instead of 4000 mg PHE.

4. Undetected cases of phenylketonuria. The question has been raised whether a risk might occur in unidentified PKU children as a consequence of the presence of aspartame in the food supply. The number of children in this category is unknown but thought to be very small. Screening of newborns for PKU is mandatory in 47 states, and it has been estimated that about 10% of the 200 PKU children born annually in the United States might remain undiagnosed and hence at great risk to grow up retarded (cf. Dr. Richard Koch's testimony at the public hearing). An undetected phenylketonuric infant would be adversely affected by the phenylalanine provided in
breast milk protein (or infant formula) which may furnish levels of phenylalanine intake in the vicinity of 80 mg/kg/day. (This compares with a projected mean phenylalanine intake from aspartame in children under 2 years of 3 mg/kg/day). The argument that aspartame in the food supply would significantly increase the risk of mental retardation in the unidentified phenylketonuric is not supported by these considerations. An undiagnosed PKU child is at risk first and foremost by being undiagnosed and hence permitted to consume meals that are standard for normal children. This point is emphasized further under the next item of consideration.

5. PKU children who are not on a restricted diet. As PKU children get older they may be allowed larger helpings of "free" food or they even go off their earlier restricted diet. This may not be harmful provided that the child's tolerance to phenylalanine is carefully monitored by blood tests. However, the question arises whether the availability of aspartame in the food supply would compromise the health and well-being of PKU children in this category. There appear to exist no explicit data based on controlled studies to answer this question, but it is possible to seek an answer by considering the amounts of phenylalanine that such children would be exposed to through usual food sources, in comparison with the PHE provided by aspartame. For example,
a 4-oz. hamburger supplies about 4000 mg phenylalanine, and a normal child would consume an average of about 200 mg phenylalanine per kg/day from normal food protein sources. This intake level compares with a projected daily aspartame-based phenylalanine intake of 17 mg/kg by those children whose aspartame consumption would reach the upper 99th percentile of the population. (For a 30-kg child this would correspond to a daily consumption of 2 helpings of aspartame-coated breakfast cereal plus 8 cans of aspartame-sweetened beverage). Thus, for children on an unrestricted diet aspartame ingestion even at this high level would contribute less than 10% of the total daily PHE intake. For children whose protein intake is restricted the relationships between food protein-derived and aspartame-derived phenylalanine would differ, but again the total intake provided by aspartame remains small. In considering the daily variation in protein intake and the concentration of phenylalanine provided by normal foods it is evident that the ingestion of aspartame could not pose a significant extra risk to PKU children whose diet is either not restricted or only partially restricted. The significant risk to their health is clearly from the phenylalanine in the protein furnished by standard foods: in a 30 kg youngster one extra hamburger would add 100-150 mg/kg, one extra hot dog about 50 mg/kg, one extra glass of milk 15 mg/kg or nearly as much as the total amount of PHE
supplied by a 34 mg/kg intake of aspartame.

6. Hyperphenylalaninemia. This term refers to a condition in which plasma-PHE levels anomalously range between 25 and 120 µmol/dl. Most of those afflicted with this abnormality are of normal intellect, and since they are usually asymptomatic also, neither they nor others are likely to be aware of their condition unless it had been identified by a newborn-screening test. The incidence of hyperphenylalaninemia is about 1/30,000, and it has been estimated that in the United States the condition affects about 1750 women of childbearing age. It is this latter category that gives the most reason for concern, since the 50% among these women who have plasma-PHE levels ranging between 60 and 120 µmol/dl are at high risk of giving birth to brain-damaged children destined to grow up mentally retarded. The only effective prevention of this consequence of hyperphenylalaninemia would consist in a systematic reduction of dietary PHE intake throughout pregnancy—in other words, in treating the prospective mother much as a phenylketonuric child would be treated. Such prophylactic measures, however, are naturally contingent upon identification of the anomalous condition before or shortly after the beginning of the pregnancy. It follows that until such time as all hyperphenylalaninemics are identified by screening tests a complete prevention of
congenital brain damage caused by maternal hyperphenylalaninemia cannot realistically be hoped for.

In evaluating the risk inherent in aspartame consumption by hyperphenylalaninemics, it is obvious that aspartame as a source of PHE can only contribute further to the already high plasma-PHE levels. It should be considered, however, that even the unlikely abuse intake of 100 mg/kg of aspartame per day by a 60-kg woman would supply less PHE (3000 mg) than would be supplied by an extra 4-oz. hamburger (4000 mg), and that the more likely (although still very high) intake of 34 mg/kg/day would be the PHE-equivalent of little more than two extra glasses of milk. It thus seems fair to conclude that the hyperphenylalaninemic woman is at much higher risk from the consumption of natural foods than she would be from the use of aspartame. It should be reiterated that the real problem of hyperphenylalaninemia lies in the usually covert nature of the anomaly.

Conclusions Regarding Aspartame-Induced Mental Retardation

In the Board's opinion, aspartame consumption by normal humans cannot be expected to increase the incidence of that particular form of mental retardation that is associated with sustained elevation of plasma-PHE levels to (or beyond) 120 μmol/dl during immature stages of brain development. This
conclusion is based on the consideration that even the highly unlikely daily consumption level of 100 mg/kg of aspartame (3 times the projected upper one-percentile of aspartame consumption) would add no more than 15-20% to the normal dietary PHE intake, less than would be added in a 60-kg individual by an extra 4-oz. hamburger. Consumed at the estimated upper one-percentile level of 34 mg/kg/day, aspartame would increase the normal daily intake of PHE by no more than six percent. These figures lie well within the limits of day-to-day variations in dietary protein consumption.

In individuals on a PHE-restricted diet designed to prevent critically elevated plasma-PHE levels, aspartame is to be handled as any other source of phenylalanine. Since these individuals (phenylketonuric children and pregnant women known to have hyperphenylalaninemia) would follow a carefully prescribed diet, a cautionary label explicitly identifying aspartame as a PHE source should forestall a liberal use of this sweetener by such patients.

In the unfortunate case of unidentified hyperphenylalaninemia, the normal food-derived PHE poses a much greater risk to the patient (or the unborn child) than would aspartame, even when consumed in very large amounts. The hyperphenylalaninemic gravis not on a PHE-restricted
diet would add 5-6% to her dietary PHE intake when consuming aspartame at the projected upper one-percentile level.

B. Focal Brain Lesions

Since first demonstrated in 1969 by Olney and co-workers in the mouse, it has become generally recognized that the acidic, dicarboxylic amino acids glutamic acid (GLU) and aspartic acid (ASP), when present in the blood plasma in adequately high concentration, can cause death of nerve cells in the central nervous system. As far as is known at present, this neuronal necrosis is focal rather than diffuse; it is certain that it preferentially affects (1) the infundibular region of the hypothalamus, (2) the so-called circumventricular organs (the area postrema, the subfornical organ, the subcommissural organ, the vascular organ of the lamina terminalis), and (3) the retina.

The evidence that acidic amino acids are potential neurotoxins naturally has raised questions with respect to the safety of aspartame as a food additive. Roughly one half of aspartame's molecular weight is contributed by its aspartic-acid moiety, and it is appropriate to ask whether its consumption could entail a risk of focal brain damage. Before considering the evidence it is necessary to point out that there are at least two reasons why this question
concerning aspartic acid cannot be examined separately and must be considered together with a similar question concerning glutamic acid, a food additive already in wide use in the United States and elsewhere: (1) both of these amino acids appear to be equipotential and mutually additive in their neurotoxic effects, and (2) a significant proportion of ingested aspartic acid in the course of its metabolism is transaminated to glutamic acid. For these reasons, it is the combined GLU-ASP content of blood plasma that ultimately must be considered, rather than the plasma ASP level alone. It is also for these reasons that the Board permitted a voluminous body of data concerning glutamic acid to be presented, even though aspartame itself is free from this amino acid.

Throughout the following survey of data it is assumed that glutamic acid or monosodium glutamate (MSG) is exchangeable with aspartic acid or sodium aspartate in the sense that the neurotoxic threshold levels of these substances in the blood plasma appear to be approximately the same.

Focal Brain Lesions Induced in Experimental Animals by Monosodium Glutamate

There is general agreement among investigators that high doses of MSG administered either by subcutaneous, intraperitoneal or intravenous injection, or by gavage
(stomach intubation), can induce hypothalamic lesions in a variety of rodent species. Of all experimental animals used in such experiments the infant mouse, 1-10 days old, has been found most vulnerable to the neurotoxic action of MSG: a single dose of 350 mg/kg injected subcutaneously, or of 500 mg/kg administered by gavage, is enough to cause, within a few hours time, a microscopically visible lesion of the hypothalamus in about half of the infant mice so treated. Correlated with this 50%-effectiveness level of intake is a rise in plasma-GLU concentration from a baseline value of about 15 μmol/dl to 100 μmol/dl. With increasing maturity mice become more resistant to MSG: in weanling mice a 50% effect requires an MSG dose of 1200 mg/kg administered by gavage and resulting in a plasma-GLU concentration of about 380 μmol/dl. In adult mice the critical plasma-GLU concentration lies near 600 μmol/dl.

Other non-primate mammalian species seem generally less vulnerable to the neurotoxic action of MSG. Although the infant rat is nearly as sensitive to MSG as the infant mouse, the 50%-effect dose in the adult rat lies near 4000 mg/kg by gavage. The critical dose in the 2-3-day old guinea pig is about 2000 mg/kg. In dogs 3-35 days old an intake of 1100 mg/kg by gavage fails to induce hypothalamic lesions, as do doses of up to 4000 mg/kg in adult dogs.
Data for the monkey are controversial. The Board is unable to resolve the conflicts that arose over this issue at the public hearing. However, to remain on the side of safety it accepts the claims: (a) that a dose of 1000 mg/kg of MSG administered by gavage or subcutaneous injection can cause microscopically detectable hypothalamic lesions in infant monkeys ranging between prematurely born and 7 days of age, and, (b) that intravenous injection of 2000 mg/kg of MSG in the pregnant monkey can induce such lesions in her fetus. Despite existing controversies the Board also accepts the suggestion that the plasma-GLU level critical for the occurrence of hypothalamic lesions in the immature monkey lies in the vicinity of 120 umol/dl.

MSG neurotoxicity in pregnant or lactating animals appears to have been studied only in a small number of species. Two separate groups of investigators have reported that in the pregnant mouse MSG must be injected in very large amounts (5000 mg/kg) to induce hypothalamic lesions in her fetuses. This finding accords well with the evidence (considered in more detail below) that the placenta in the monkey maintains a highly effective barrier against both GLU and ASP: only at grossly elevated maternal plasma-GLU levels (280 umol/dl) does GLU in this mammalian species begin to enter the fetal circulation. A somewhat similar barrier appears to be maintained by the mammary gland: in the
lactating human female at least, the ingestion of relatively high doses of MSG does not significantly affect the GLU content of her milk (see below).

**Dietary intake of MSG by experimental animals.** In all of the animal experiments mentioned in the foregoing account, MSG was either injected, or administered by stomach tube in the form of an aqueous solution. Markedly different effects upon plasma-GLU concentrations have been reported from experiments in which mice were given MSG mixed with food. Mixed with "infant formula" or with a "soup diet," and administered by stomach tube, MSG in weanling mice has been reported to induce a rise of the plasma-GLU concentration only one-fifth to one-third as large as that caused by the same amount of MSG mixed with water. Ingested by adult mice as a food additive in the enormous amount of 20,000 mg/kg, MSG has been reported to induce peak plasma-GLU concentrations no higher than 174 pmol/dl, little more than one-quarter of the plasma level (630 umol/dl) that is correlated with hypothalamic lesions caused by subcutaneous injection of 1500 mg/kg MSG. It is relevant in this context that the archival literature includes no report of brain lesions induced in any species by dietary intake of any amount of MSG.
A postscript to these negative findings must be made. In a post-hearing communication dated April 3, 1980, to the Board and to his co-participants in the hearing, Dr. Olney reported having found clear-cut hypothalamic lesions in all of 10 weanling mice who--after having been deprived of water overnight--had drunk 0.2-0.35 ml of either a 10% aqueous GLU (presumably l-glutamic acid) solution or a solution containing 6.5% GLU, 3.5% ASP, and 1% aspartame, while concurrently consuming an unspecified amount of Purina mouse chow. The Board accepts this evidence (acknowledging that it stands at present unconfirmed) and considers that it imposes a qualification upon those statements according to which no focal brain lesions have been induced in any species by voluntary consumption of any amount of GLU or its monosodium salt. A rough calculation suggests that the weanling rats had ingested a minimum of 13 mg of GLU with the drinking water. Assuming that body weights ranged between 10 and 15 g, this intake corresponds to a loading dose of 900 mg/kg to 1300 mg/kg body weight.

**Focal Brain Lesions Induced in Experimental Animals by Aspartame**

In the infant mouse, 2000 mg/kg aspartame administered by gavage in the form of an aqueous slurry has been reported
to cause hypothalamic lesions in 39% of subjects. No such lesions were found in any 9-day old mouse given 500 mg/kg aspartame by gavage. It seems reasonable to assume that in the infant mouse the risk of hypothalamic lesion begins to arise at a dose level of 1000 mg/kg aspartame administered by gavage. This dose approximately corresponds to 500 mg/kg aspartic acid.

Since neither the same dose nor very much higher doses of aspartame consumed by immature mice as part of the daily diet have been found to induce endocrine disorders (see below) it seems warranted to conclude that the resorption and/or metabolism of aspartic acid depends upon the route by which this amino acid is administered. Much like MSG, aspartic acid ingested as a food additive has been reported to induce elevations of the plasma-ASP level smaller than those induced by aspartic acid administered by gavage or subcutaneous injection. Further data concerning this point will be considered in a subsequent review of aspartame consumption in the human.
Neuroendocrine Disorders Induced by MSG and Aspartame in Experimental Animals

In view of the topographic characteristics of its neurotoxic effects it is not surprising that MSG administered in large amounts by subcutaneous injection has been found to induce endocrine disorders in mice, rats, and hamsters. In all of the studies from which such disorders were reported, subjects had received either a single subcutaneous injection of 3000 mg/kg MSG on the second postnatal day, or a daily injection of 2200-4000 mg/kg for 10 days starting on day 2. Prominently listed among the consequences of such treatments are: stunting of body growth, obesity, and sterility in the female. Although apparently not explicitly demonstrated thus far, it seems reasonable to assume that in the same species subcutaneous injection of similar amounts of aspartate, or administration of aspartame by gavage in twice these amounts, would have similar endocrine consequences. It must be stressed, however, that no studies concerning the endocrine effects of subcutaneous or intragastric administration of either MSG or aspartate appear to have been done in species other than rodents. Hence, at present nothing can be said concerning the relative susceptibility of the endocrine system of various non-rodent species to parenterally administered MSG or aspartate.
Neuroendocrine Effects of Sub-neurotoxic Doses of MSG and Aspartame

One of the objecting parties has stressed the possibility that a routine intake of MSG or aspartame several times a day by children throughout their formative years could entail repetitive disturbances in several neuroendocrine axes (e.g., gonadotropins, growth hormone, and prolactin) and that such perturbations could adversely affect somatosexual development. According to this suggestion, neuroendocrine disorders induced by MSG or aspartame need not be associated with anatomically demonstrable lesions of the hypothalamus, and can be caused by an imbalance of hypothalamic function resulting from the neuroexcitatory effect of glutamate and aspartate. The notion is based upon a report by the objecting party according to which a subcutaneous injection of MSG in the presumably sub-neurotoxic amount of 1000 mg/kg in the adult rat markedly elevates plasma levels of luteinizing hormone (LH) and testosterone (TS). It was pointed out at the hearing, however, that quantitatively similar fluctuations of LH and TS levels occur normally in the course of each 24-hour period, and that the reported increases may thus have reflected no more than a normal circadian or ultradian periodicity of LH and TS release. Moreover, in two other
published studies no correlation between MSG injections and fluctuations of LH and TS levels could be demonstrated.

The suggestion that a routine intake of aspartame during immature stages of development can entail an impairment of sexual function in later life would seem effectively refuted by the results of a long-term study of the effects of aspartame consumption on reproductive function in the rat. In this study, a daily dietary intake of very large amounts of aspartame ranging between 1800 and 3700 mg/kg, beginning on postnatal days 10-20 and ending on days 90-100, did not affect fertility, gestation, live birth, litter size, or nursing in either the experimental subjects or their offspring. The results of several further studies presented at the hearing likewise indicate that endocrine disorders are induced by MSG only when this substance is administered in amounts large enough to cause identifiable hypothalamic lesions. The experimental evidence thus appears to argue against the notion of sub-neurotoxic effects upon the neuroendocrine axis.

**Glutamate and Aspartame Consumption in the Human**

Among the data presented on this subject, the Board considers the following pragmatic evidence of particular relevance.
1. In the adult, a loading dose of 34 mg/kg aspartame (the 95th percentile of a projected mean daily consumption of 7-9 mg/kg, and roughly equivalent to 100 tablets of 20 mg aspartame) dissolved in orange juice induces no significant elevation of either plasma GLU or plasma ASP concentration. Neither does a loading dose of 50 mg/kg aspartame induce any significant rise of GLU or ASP concentration in either blood plasma or erythrocytes.

2. A similarly administered aspartame loading dose of 200 mg/kg in the adult (equivalent to 600-800 aspartame tablets) causes the plasma ASP level to rise from a baseline of 0.2 μmol/dl to 1 μmol/dl, receding to baseline in 3 hours. Following such a dose, the plasma GLU level rises from 2.5 μmol/dl to 6 μmol/dl for a combined plasma GLU + ASP rise to 7 μmol/dl.

3. A hamburger-milkshake meal providing 1 g of protein per kg body weight, and containing free plus protein-bound GLU in the amount of 171-198 mg/kg body weight and free plus protein-bound ASP in the amount of 90-103 mg/kg body weight, causes an elevation of the plasma GLU level from a baseline of 4 μmol/dl to 9 μmol/dl, and raises the plasma ASP level from a baseline of 0.3 μmol/dl to 0.8 μmol/dl. The addition of 34 mg/kg MSG (the 90th percentile of projected MSG consumption) to this meal has no effect upon these
post-prandial elevations, and neither does the addition to the meal of 34 mg/kg MSG plus 34 mg/kg aspartame. If the MSG addition to the meal is increased to 150 mg/kg the plasma GLU + ASP level rises from a baseline of 5 μmol/dl to 25 μmol/dl; the addition of 34 mg/kg aspartame in this case causes no further increase in the plasma GLU + ASP level.

4. In one-year-old infants, a loading dose of 100 mg/kg aspartame induces a rise of the plasma ASP level from a baseline of 1.5 μmol/dl to 2.6 μmol/dl, receding to baseline in 1-2 hours. This finding appears to refute any suggestion that aspartic acid might be metabolized less efficiently in infants than in adults.

5. In PKU heterozygote adults aspartame loading doses of 34 mg/kg and 100 mg/kg are metabolized much as they are in normal individuals. The resulting rise in plasma GLU level is virtually the same in both categories of subjects, while the rise in plasma ASP level is slightly, but not significantly, higher: plasma GLU + ASP level reaches a mean of 4.5 μmol/dl in normal adults, a mean of 4.8 μmol/dl in PKU heterozygote adults.

6. In the lactating woman, a loading dose of 50 mg/kg aspartame (about 150 aspartame tablets) induces no significant elevation of plasma ASP or GLU levels. This
dosage raises the ASP concentration in her milk from 2.3 to 4.8 umol/dl, the GLU concentration from 109 to 120 umol/dl. At this high level of maternal aspartame intake, the breast-fed infant's normal daily intake of 366 mg/kg GLU + ASP is increased by no more than 0.77 mg/kg.

7. **Placental transfer of ASP to the fetus**. For obvious reasons, this problem cannot be directly approached experimentally in the human. The following conclusions are based upon experiments in pregnant monkeys.

The primate placenta maintains a 1:2 plasma-concentration gradient toward the fetal circulation for most amino acids. However, both GLU and ASP are exceptions to this rule. GLU is not transferred at all from the maternal to the fetal circulation even when the maternal plasma level is increased from a baseline of 5 umol/dl to 55 µmol/dl; only at the enormously elevated maternal plasma GLU level of 280 umol/dl—induced by direct intravenous infusion of GLU—does some transfer to the fetus take place. The placenta maintains an equally effective barrier against ASP: intravenous infusion of 100 mg/kg ASP (in one hour) elevates the maternal ASP level from a baseline of 0.4 umol/dl to 80 umol/dl; the fetal plasma ASP level under these conditions does not exceed 0.42 umol/dl. Maternal ASP infusion of 200 mg/kg/hr induces a maternal plasma ASP rise to 237 umol/dl,
while the fetal plasma ASP level rises from a baseline of 0.6 umol/dl no further than 4.5 umol/dl.

Taken together with items 1 and 2 above, these findings indicate that both mother and fetus are thoroughly protected against hazardous plasma ASP levels: the mother by a highly effective barrier of ASP resorption and/or metabolism, the fetus in addition by an equally effective placental barrier. The mother herself has no comparably effective defense against GLU, but plasma GLU levels high enough to place her at risk are not reflected in the fetal blood plasma.

Risk Evaluation

In attempting to assess the risk of focal (in particular, hypothalamic) brain damage connected with human aspartame consumption, the Board decided to adopt a 100 umol/dl concentration of GLU + ASP in the blood plasma as the critical level. This conservative assumption was made for reasons of caution: 100 µmol/dl is the concentration at which a 50% occurrence of focal brain lesions has been reported for the infant mouse, the animal form generally thought to be most sensitive to the neurotoxic effects of glutamic and aspartic acid. The problem thus became reduced to the question whether, and at what level of consumption by the human, aspartame could induce plasma GLU + ASP elevations
approaching the 100 μmol/dl level when taken alone, or alternatively, whether it could significantly contribute to such elevations induced by MSG consumption. It should be recalled in this connection that—unlike the brain damage associated with phenylalanine—the focal brain lesions associated with GLU and ASP neurotoxicity are not contingent upon a long-maintained high plasma concentration of the causative agent: it is evident from animal experiments that focal hypothalamic lesions can be induced by a single elevation of the plasma GLU and/or ASP concentration to the level of 100 umol/dl.

It is of some historic interest that much of the evidence reported to the Board concerning the aforementioned question dates from recent years (1976-1979), and consequently was not available at the time the objections to the approval of aspartame as a food additive were originally filed. With a single exception, the following statements can at present be considered justified by the results of experiments done directly in the human rather than in one or more animal species:

1. The human organism, infant as well as adult, is protected against high surges of ASP concentration in either blood plasma or erythrocytes by a biological barrier mechanism presumably located in the gastrointestinal mucosa.
and/or liver. The effectiveness of this protective mechanism is illustrated by the observation that loading doses of aspartame as high as 200 mg/kg body weight (in a 60 kg individual equivalent to 600 aspartame tablets or 20 liters of aspartame-sweetened beverage consumed in a single sitting) induces an elevation of plasma and erythrocyte GLU + ASP concentration of no more than 5 umol/dl above a baseline level of 2.5-3 umol/dl. It is of added significance that these elevations are short-lived, receding to baseline in about 3 hours time. It follows that repeat-doses of the same enormous magnitude, when spaced 3 hours apart, are unlikely to escalate the GLU + ASP concentration much beyond the level induced by the first dose.

2. The ASP plasma-entry barrier is unaffected by simultaneously ingested MSG: the 25 umol/dl plasma GLU + ASP concentration achieved by adding to a protein-rich meal a very large dose of MSG (150 mg/kg, or 9000 mg in the case of a 60 kg person) is not augmented by the further addition of 34 mg/kg aspartame (100 aspartame tablets) to the meal.

3. The PKU heterozygote adult is no less effectively protected against aspartame-induced surges of plasma GLU + ASP concentration than the normal human.
4. In the breast-fed infant, a consumption of 50 mg/kg aspartame by the lactating mother results in an increase of no more than 0.77 mg/kg GLU + ASP over the normal daily intake of 366 mg/kg GLU + ASP.

5. The speculation that aspartame consumption by the pregnant woman could expose her fetus to a high risk of focal brain damage cannot be investigated directly in the human. However, experimental findings in the monkey indicate that the primate placenta maintains a nearly insurmountable barrier against any transfer of GLU and ASP from the maternal to the fetal circulation.

Conclusion Regarding Aspartame-Induced Focal Brain Lesions

In the Board's opinion, the most pertinent evidence presented at the public hearing convincingly demonstrates that the risk of focal brain damage associated with aspartame consumption in the human is negligible. Elevations of plasma GLU + ASP concentration even to the lowest level that could be suspected of being neurotoxic (100 μmol/dl) would require an inconceivably high oral aspartame intake. Such levels might in fact prove attainable only by parenteral ASP administration designed to bypass the highly effective intestinal and/or hepatic barrier mechanism guarding against surges of plasma ASP concentration.
C. Conclusion Concerning Issue Number 1

On the basis of the data reported at the public hearing, the Board concludes that the ingestion of aspartame, either alone or together with glutamate, cannot be expected to increase the incidence of mental retardation, brain damage, or dysfunction of neuroendocrine regulatory systems.

IV. ISSUE NUMBER 2

The question has been raised whether the ingestion of aspartame may induce brain neoplasms in the rat. From available evidence, what can be concluded in relation to this question? The objecting parties believe that available evidence suggests, without adequately ruling out, a possible association between aspartame ingestion and an increased incidence of brain neoplasms in the rat. The Bureau of Foods believes that available evidence does not show that ingestion of aspartame results in an increased incidence of brain neoplasms in the rat. 44 Fed. Reg. 31717.

With respect to this question, it must be emphasized that the Board was compelled to base its judgment on no more than three studies in which the problem of aspartame's possible oncogenicity was systematically investigated. All three were reported by the defending party. In one of these studies (EJ3/34), four groups each of 80 rats of the Charles River/Sprague-Dawley strain were given doses of,
respectively, 1000, 2000, 4000, and 6000-8000 mg aspartame per kg body weight per day, starting after weaning and continuing over two years; a group of 119 rats served as untreated controls. In a second study (E70), two groups of, respectively, 78 and 79 rats were given a daily dose of, respectively, 2000 and 4000 mg/kg aspartame for two years; these rats were the offspring of two groups of parents who had been fed the same daily doses of aspartame, starting 60 days prior to mating and continued (in the mothers) throughout gestation and lactation; 115 rats served as untreated controls in this experiment. Finally, in a third study (E77/78), the diketopiperazide (DKP) of aspartame was examined for possible oncogenic effects by feeding this compound to three groups of, respectively, 68, 66, and 64 rats in daily doses of, respectively, 750, 1500, and 3000 mg/kg, starting at 4 weeks and continued for 115 weeks; 123 rats were included in this study as untreated controls. From the submitted reports, and from a personal viewing of the histopathological material, the Board extracts the following accounting:

1. In experiment E33/34 a total of 13 brain tumors were found, 8 of which were large enough to have been noted upon gross examination, and 6 of which may have contributed to death before the end of the second year of life. In the control group of 119 rats one brain tumor was found; it
consisted of a small, circumscribed nodule, most likely a metastatic carcinoma. In the second group (1000 mg/kg aspartame/day), 4 gliomas were found; two of these were small astrocytomas, the remaining two large, grossly visible, more anaplastic gliomas (one of the latter caused--or contributed to--death at 8 weeks). In the third group (2000 mg/kg/day) a large glioma may have contributed to death at 16 weeks. In the fourth group (4000 mg/kg/day) 5 gliomas were found, two of which must have been noted at autopsy and may have been the principal cause of death at 84 and 100 weeks, respectively. In the fifth group (6000-8000 mg/kg/day) two brain tumors, a glioblastoma and a medulloblastoma, caused death at 66 and 12 weeks, respectively.

This study indicates a brain-tumor incidence of 0.8% in the control group (1/119) and 3.75% in the aspartame-fed rats. In view of the small number of 80 rats in each experimental group, the two relatively low-dose (1000-2000 mg/kg/day) groups could be combined, as well as the two high-dose groups. This would yield a figure of, respectively, 5 brain tumors in 160 rats (3.1%), and 7 in 160 rats (4.3%), suggesting a possible dose-effect relationship. Furthermore, it is noted that 8 of the 12 tumors in aspartame-fed rats developed at less than 2 years of age. The argument that the medulloblastoma should not be included in the calculations cannot be accepted. In the human,
medulloblastomas are known to occur not only in infancy but also in older children, in adolescents, and occasionally even late in life. Moreover, in the oncological literature two medulloblastomas have been reported in adult Sprague-Dawley rats subjected to whole-body radiation.

2. In the E70 study 8 tumors were found in a total of 272 rats, corresponding to a combined incidence of 2.9%. Three of these 8 tumors were large enough to be identified grossly at the time of autopsy.

The most remarkable aspect of this study is the high incidence of brain tumors in the control group: 4 gliomas in 115 rats, or 3.5%. The remaining four tumors were found in the 157 rats exposed to aspartame from conception to 2 years of age: 2 gliomas in the low-dose group (2000 mg/kg), one glioma and meningioma in the high-dose group (4000 mg/kg), for a combined incidence of 2.5% brain tumors, or 1.9% gliomas, in the two experimental groups.

The overall incidence of 2.6% gliomas in this study (control plus aspartame-fed animals) is the highest thus far reported from lifetime studies on this strain of rats. Its most puzzling aspect is the 3.5% incidence of gliomas among the 115 control animals, a very high figure in comparison with the 0.8% incidence among the 119 control animals of the E33/34 study.
3. In the 77/78 study concerning the diketopiperazide of aspartame 5 tumors were recorded: 2 in the control group of 123 rats (1.6%), the remaining 3 among the 198 animals of the three experimental groups (1.5%). Two of the 5 gliomas could have been noted on gross inspection of the brain.

This study shows no difference between experimental and control groups, and the recorded percentages fall within the high range of normal incidence reported from various normative studies.

"Spontaneous" Occurrence of Brain Tumors Among Sprague-Dawley Rats

It is difficult to conclude from the archival literature which of various published figures most accurately reflects the "normal" (i.e., presumably non-toxogenic) incidence of brain tumors in the Sprague-Dawley rat strain. Several published reports are based on findings in rats that had been used in long-term studies designed to check the potential toxicity of a particular chemical compound, or of irradiated foods. Other reports fail to state the protocol followed in examining the brain for tumors: gross-anatomical tumor identification only, or routine histological examination of each brain? From the heterogeneous volume of published data, the Board selected the following as most significant; first
of all because they seem most nearly normative (no potential toxins were added to the diet), and, second, because the brains were routinely examined histologically.

1. Thompson et al. (J. Nat'l Cancer Institute, vol. 27, 1961) recorded 4 brain tumors (3.2%) during the life span (7–32 months) of 125 Sprague-Dawley rats. All occurred at less than 2 years of age. One of the tumors was a glioma (ependymoma), one a choroid plexus papilloma, one a meningioma, and one a pinealoma (germinoma). The incidence of gliomas in this study was 0.8% or 1.6% depending on whether the papilloma is considered a glioma. The number of rats used in this study is too small for a reliable determination of spontaneous-tumor incidence.

2. Hawdesley-Thomass and Newman (J. Pathol., vol. 112, 1974) found 38 tumors of the central nervous system in 41,000 Sprague-Dawley rats (0.09%), seven of which were noted at autopsy. Half of the tumors occurred after two years of age; at 112 weeks only 20 tumors (0.046%) had been encountered. Of the 38 tumors, 22 were gliomas, 13 meningiomas, and 3 sarcomas.

3. Fitzgerald et al. (J. Nat'l Cancer Institute, vol. 52, 1974) recorded 5 brain tumors in 650 rats: 4 astrocytomas and one meningioma (0.7%).
To these three papers could be added one further publication, by McKenzie and Garner (J. Nat'l Cancer Institute, vol. 50, 1973), in which 535 rats were examined that had been used in a 2-year study on the effects of irradiated-food consumption. In this population, 3 brain tumors, all gliomas, were found (0.6%).

According to these data, the "spontaneous" CNS-tumor incidence in Sprague-Dawley rats varies between 0.09% (Mawdesley-Thomas and Newman) and 3.2% (Thompson et al.). In this context a remark by McKenzie and Garner is of interest, according to which the tumor incidence in different groups of "Sprague-Dawley" rats supplied by different commercial sources differs from group to group as much as it differs between the Sprague-Dawley and other rat strains. It is therefore of possible significance that the Charles River CD line of Sprague-Dawley rats used in the studies E33/34, E70 and E77/78 was also used by Fitzgerald et al. who arrived at a 0.7% incidence of brain tumors and by McKenzie and Garner who reported a 0.6% incidence.

**Evaluation**

The problem of aspartame's possible oncogenicity clearly is a complex issue, difficult to judge fairly on the basis of available data. Even with this reservation in mind, the
Board finds reason to be concerned about the evidence submitted at the public hearing. Its concern rests mainly on the outcome of study E33/34, as set forth in the following account.

In study E33/34, a total of 320 rats received large quantities of aspartame as a food additive. Twelve tumors were found in these rats, 11 of which—almost 90%—were gliomas. By itself, the 3.5% incidence of brain tumors gives cause for concern, and this is only augmented by the high incidence of gliomas at relatively early age: 5 rats died with glioma before completing the second year of life. In the low-dose group (1000 mg/kg aspartame) one died at 8 weeks of a large glioma; in the 2000 mg/kg group one died of glioma at 16 weeks; the 3000 mg/kg group had one death of glioma at 84 weeks and one at 100 weeks, while there was one death of glioblastoma at 66 weeks in the 6000-8000 mg/kg group. Thus, study E33/34 yielded two deaths of glia-cell tumor in the first year of life, and one at 66 weeks. By contrast, in Newnesley-Thomas and Newman's normative study involving 41,000 Sprague-Dawley rats no brain tumors were found in rats younger than 60-70 weeks.

A further cause for concern in study E33/34 is presented by the suggested dose-effect relationship: whereas the
combined brain tumor incidence in the two lower-dose groups was 3.1%, it was 4.3% for the two higher-dose groups.

The outcome of the E70 study is puzzling. In the Board's opinion, this critically important study should have included a larger number of experimental animals. As it stands, it is difficult or even impossible to evaluate with respect to the significance of the findings. All that can be said of the results of this study is that the 3.5% incidence of gliomas among the 115 control animals is bizarre when compared with the brain tumor incidence reported from normative studies on the Charles River CD line of Sprague-Dawley rats (Fitzgerald et al.: 0.7%; McKenzie and Garner: 0.6%), and that the 2.5% incidence among the aspartame-treated groups likewise lies well above the normative figures.

Comment

The foregoing considerations leave the Board no choice but to conclude that the data reported at the public hearing, when taken at face value, do not rule out an oncogenic effect of aspartame, and that, to the contrary, they appear to suggest the possibility that aspartame, at least when administered in the huge quantities employed in these studies, may contribute to the development of brain tumors.
The Board submits that the supranormal incidence of brain tumors in the reported studies may be related to the enforced consumption, throughout a lifetime, of quantities of aspartame enormous enough to cause a sustained and profound imbalance in the amino acid composition of blood plasma and other tissue fluids. This raises the question whether aspartame and other peptides might need to be tested for oncogenicity by a protocol different from that employed in the testing of compounds that are not, as aspartame is, entirely composed of amino acids normally present in tissue fluids. Such non-peptidic compounds might not so predictably disrupt the amino acid balance when ingested in quantities one-hundred or more times higher than any foreseeable human use. Because of this consideration, the Board suggests that experiments with aspartame doses closer to the projected human consumption level (e.g., 100 and 200 mg/kg) be included in future repetitions of the oncogenicity studies reported at the hearing.

Conclusion Concerning Issue Number 2

The Board concludes that the reported data suggest the possibility of an oncogenic effect of aspartame ingestion at the extremely high level of 1000-6000 mg/kg throughout the rat's lifetime. Yet, the exclusive use of such extreme dosage in the screening of compounds consisting entirely of
amino acids normally present in blood plasma needs be questioned, for the outcome might reflect no more than a non-specific effect of an artificially maintained gross imbalance in the amino acid composition of the tissue fluids.

V. ISSUE NUMBER 3

Based on answers to the above questions,
(a) Should aspartame be allowed for use in foods, or, instead should approval of aspartame be withdrawn?
(b) If aspartame is allowed for use in foods, i.e., if its approval is not withdrawn, what conditions of use and labeling and label statements should be required, if any? 44 Fed. Reg. 31717.

On the basis of the conclusion concerning Issue Number 2, the Board concludes that approval of aspartame for use in foods should be withheld at least until the question concerning its possible oncogenic potential has been resolved by further experiments. The Board has not been presented with proof of a reasonable certainty that aspartame is safe for use as a food additive under its intended conditions of use.
VI. ORDER

The foregoing constitutes the Board's findings of fact and conclusions of law.

Therefore, it is ORDERED that:

1. Approval of the food additive petition for aspartame (FAP 3A2885) be and it is hereby withdrawn.

2. The stay of the effectiveness of the regulation for aspartame, 21 CFR 172.804, is hereby vacated and the regulation revoked.

3. Pursuant to 21 CFR 12.125, exceptions to this Initial Decision must be received by the Hearing Clerk within 30 days; replies to exceptions must be received by the Hearing Clerk not more than 20 days thereafter. In the absence of the timely filing of exceptions, or of a review notice by the Commissioner under 21 CFR 12.125(f), this Initial Decision will become the Final Decision of the Commissioner upon the expiration of the date for filing for
appeal or review, and shall be effective upon publication of a notice to that effect in the Federal Register.

Dated this 30th day of September, 1980.

[Signature]
Walle J. H. Nauta
Walle J. H. Nauta, M.D., Ph.D.
Chairman

[Signature]
Peter W. Lampert, M.D.
Member

[Signature]
Vernon R. Young, Ph.D.
Member

ASPARTAME PUBLIC BOARD OF INQUIRY